多西他塞联合甲地孕酮治疗激素抵抗性前列腺癌疗效观察

目的观察多西他塞联合甲地孕酮治疗治疗激素抵抗性前列腺癌的疗效和毒副作用。方法21例经雄激素阻断治疗失败的雄激素抵抗性前列腺癌患者采用多西他塞联合甲地孕酮治疗,多西他塞75mg/m2静脉滴注d1,8,甲地孕酮160 mg/d,连续口服,28 d为1周期。直至病情进展或毒副反应患者无法耐受。结果21例平均随访15个月,PSA缓解率61.9%,有效持续时间平均12.6个月,9例可测量病灶,有效率66.7%,CR44.4%,PR22.2%,疼痛缓解率47.6%,其中疼痛缓解时间平均为16个月,全组中位生存期13个月,1年生存率47.6%。毒副反应为胃肠道反应和骨髓抑制。结论多西他塞联合甲地孕酮治疗激素抵抗性前列腺癌的临床疗效显著,毒副反应可以耐受,可作为激素抵抗性前列腺癌的一种治疗方法。

Analyses of clinical results of treatment with docetaxel and megestrol acetate for treating hormone-resistance prostate carcinoma

Objective To evaluate the efficacy of docetaxel and megestrol acetate combination in the treatment of treating hormone-resistance prostate carcinoma(HRPC).Methods Between June 2003 and January 2005,21 patients with treating hormone-resistance prostate carcinoma were treated with docetaxel and megestrol acetate combination,docetaxel 75mg/m2 ivdrip d1,8;oral megestrol acetat 160mg/d,d1～28,28 days as a cycle.The therapy was continued until there was evidence of disease progression or the patients could not tolerate the adverse effects of the medications.Result All the 21 patients had a mean follow-up of 15 months,The response rate of PSA was(61.9%),The mean duration of response was 12.6 months(range,2-15months).Of the 9 cases with objective areas,there was an response rates of 66.7%、complete response rates of 44.4%、partal response rates of 22.2%.The pain-alleviation rates was 47.6%,the mean pain-alleviation time was 13 months. The median survivalperiod was 13 months,1-years survival rates was 47.6%.Toxic and adverse effects were gastrointestinal reaction and hematological toxicity.Conclusions The combination of docetaxel and megestrol acetate may be an efficacious and well-tolerated regimen for treating hormone-resistance prostate carcinoma(HRPC).